MindWalk Holdings Corp.

NASDAQ:HYFT

Biotechnology

Healthcare
$1.08 +0.33%

+$0.01 today

Market cap
$50.88M
Beta
0.82
P/E (TTM)
-8.1
EPS (TTM)
-$0.26
52W Low $0.82High $3.25

Volume 0.20M

Average 0.32M

HYFT Acquisitions (Net)

Cash paid for acquiring businesses, net of cash acquired.

MindWalk Holdings Corp.NASDAQ: HYFT

Acquisitions (Net) · Q3 FY2026 · quarter ended Jan 2026

Acquisitions (net) outflow grows to CA$14.26M

Q3 FY2026 acquisitions (net) was CA$14.26M, compared with CA$0 a year earlier. Trailing-twelve-month acquisitions (net) was CA$13.94M.

Context

  • Acquisitions (net) amounted to 0.0% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Acquisitions (net) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly acquisitions (net) holds near CA$14.26M or moves back toward the trailing-twelve-month quarterly average of CA$3.49M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJan 2026
CA$14.26M— QoQ
Last fiscal yearApr 2025
CA$0+100.0% YoY
LTMJan 2026
CA$13.94M— YoY
Acquisitions (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Acquisitions (Net) history

CAD · from the cash flow

Latest · FY2025
0 CAD
Year-over-year change
+100.0%

Acquisitions (Net) vs competitors

How HYFT compares with its peers on the latest reported figures

  • Peers report in different currencies, so acquisitions (net) is compared through growth and share of revenue rather than absolute size.
  • Acquisitions (net) amounts to 76.0% of revenue for HYFT, versus a peer median of 2.2%.
HYFT Competitors
Acquisitions (Net) for HYFT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$13.94M CAD——76.0%
BYSIBeyondSpring Inc.LTM Mar 2026$3.09M USD———
FBIOFortress Biotech, Inc.LTM Mar 2026$2.87M USD——4.3%
ATYRaTyr Pharma, Inc.LTM Mar 2026$12K USD+71.4%—6.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$0 USD——0.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$0 USD———
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$0 USD———
CLNNClene Inc.LTM Mar 2026$0 USD——0.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding HYFT) —+71.4%—2.2%

Competitors are the stored peer set for HYFT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Net Income(7.34M)(16.71M)(26.56M)(27.18M)(30.23M)
Depreciation & Amortization3.71M3.77M6.69M5.74M5.12M
Deferred Income Tax(83K)(336K)(926K)(1.77M)(3.94M)
Stock-Based Compensation2.75M3.08M1.94M1.54M445K
Change in Working Capital(1.02M)582K(3.28M)2.4M276.99K
Accounts Receivables(439K)163K(561K)(241K)(391.8K)
Inventory(316K)(501K)(185K)(102K)99.03K
Accounts Payables(73K)781K(1.55M)994.8K593.45K
Other Working Capital(190K)139K(976K)1.75M(23.68K)
Other Non-Cash Items1.38M(310K)2.3M15.03M21.92M
Operating Cash Flow(600K)(9.92M)(19.83M)(4.25M)(6.41M)
Capital Expenditures(1.43M)(1.26M)(1.5M)(1.4M)(799K)
Acquisitions (Net)(1.03M)(3.69M)(592K)(146K)0
Purchases of Investments00000
Sales of Investments0080K121K0
Other Investing Activities0(259K)40K(141K)0
Investing Cash Flow(2.46M)(5.21M)(1.97M)(1.56M)(799K)
Debt Repayment(772K)(962K)(1.34M)(1.34M)2.67M
Common Stock Issued44.15M3.85M716K1.75M12.23M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(5K)0612.26K0
Financing Cash Flow43.38M2.88M(621K)1.02M14.89M
Effect of Forex Changes(1.18M)455K740K(33K)(438K)
Net Change in Cash39.15M(11.79M)(21.68M)(4.82M)7.25M
Free Cash Flow(2.03M)(11.18M)(21.33M)(5.64M)(7.21M)

MindWalk Holdings Corp.

NASDAQ:HYFT

Intrinsic Alpha fair value

Locked

Current Price

$1.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.